| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/24/2009 | CA2718950A1 Bridged heterocycles as hiv integrase inhibitors |
| 09/24/2009 | CA2718936A1 Novel heterocyclic compounds and uses therof |
| 09/24/2009 | CA2718872A1 Novel tyrosine kinase inhibitors |
| 09/24/2009 | CA2718772A1 Crystal forms of 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nit robenzene-1,2-diol |
| 09/24/2009 | CA2718744A1 Novel 1,2,4-triazole derivatives and process of manufacturing thereof |
| 09/24/2009 | CA2718736A1 Pyrrolidinyl derivatives and uses thereof |
| 09/24/2009 | CA2718723A1 Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| 09/24/2009 | CA2718713A1 Therapeutic compounds |
| 09/24/2009 | CA2718705A1 S1p3 receptor inhibitors for treating inflammation |
| 09/24/2009 | CA2718697A1 Extended release formulation containing a wax |
| 09/24/2009 | CA2718693A1 Substituted pyrazolamides and the use thereof |
| 09/24/2009 | CA2718685A1 (pyrazolyl carbonyl)imidazolidinone derivatives for the treatment of retroviral diseases |
| 09/24/2009 | CA2718640A1 Enteral nutrient |
| 09/24/2009 | CA2718560A1 Therapeutic agent for fibroid lung |
| 09/24/2009 | CA2718558A1 Midazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as_melanocortin-4 receptor modulators |
| 09/24/2009 | CA2718551A1 Substituted sulfonamide derivatives |
| 09/24/2009 | CA2718528A1 Substituted 4-hydroxypyrimidine-5-carboxamides |
| 09/24/2009 | CA2718526A1 Organic compounds |
| 09/24/2009 | CA2718264A1 Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| 09/24/2009 | CA2718231A1 Emulsions including a peg-derivative of tocopherol |
| 09/24/2009 | CA2718123A1 Quinazoline derivatives as raf kinase modulators and methods of use thereof |
| 09/24/2009 | CA2718076A1 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts |
| 09/24/2009 | CA2717958A1 Dithiocarbamate metal chelates and methods of making and using thereof |
| 09/24/2009 | CA2717934A1 Process for the preparation of 2-amino-2- [2-(4-c3-c21-alkyl-phenyl)ethyl] propane-1,3-diols |
| 09/24/2009 | CA2717922A1 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists |
| 09/24/2009 | CA2717899A1 Stable fixed dose topical formulation |
| 09/24/2009 | CA2717679A1 Aqueous pharmaceutical compositions containing borate-polyol complexes |
| 09/24/2009 | CA2717440A1 Antiviral formulation |
| 09/24/2009 | CA2717419A1 Synergic 5'-methylthioadenosine combinations |
| 09/24/2009 | CA2717365A1 Methods of treating inflammation |
| 09/24/2009 | CA2716994A1 Pharmaceutical compositions having desirable bioavailability |
| 09/24/2009 | CA2716921A1 Quinolizidinone m1 receptor positive allosteric modulators |
| 09/24/2009 | CA2716856A1 Aurora kinase modulators and method of use |
| 09/24/2009 | CA2716592A1 Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| 09/24/2009 | CA2716448A1 Dosing regimen for a selective s1p1 receptor agonist |
| 09/24/2009 | CA2716035A1 Novel 3-aminoalkyl-1,3-dihydro-2h-indol-2-one derivatives, preparation thereof and therapeutic use thereof |
| 09/24/2009 | CA2715422A1 Compositions for site-specific delivery of imatinib and methods of use |
| 09/24/2009 | CA2715350A1 Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic |
| 09/24/2009 | CA2715272A1 A high throughput protein interaction assay |
| 09/24/2009 | CA2715096A1 5.6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as antagonists for urotensine ii receptors |
| 09/24/2009 | CA2714662A1 Trisubstituted 1,2,4-triazoles as nicotinic acetylcholine receptor modulators |
| 09/24/2009 | CA2714184A1 Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria |
| 09/24/2009 | CA2712705A1 Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| 09/24/2009 | CA2711569A1 Composition and methods used during anti-hiv treatment |
| 09/24/2009 | CA2710811A1 N-phenyl-imidazo[1,2-a]pyridine-2-carboxamide compounds, preparation thereof and therapeutic application thereof |
| 09/23/2009 | EP2103689A1 Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| 09/23/2009 | EP2103631A1 Mercapto-group modified macromolecule derivative and cross-linked material |
| 09/23/2009 | EP2103620A1 Fused heterocyclic compound |
| 09/23/2009 | EP2103619A1 Imidazothiazole derivatives |
| 09/23/2009 | EP2103618A1 Novel ansamitocin derivatives |
| 09/23/2009 | EP2103614A1 Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators |
| 09/23/2009 | EP2103613A1 Quinoxaline derivative |
| 09/23/2009 | EP2103612A1 Crystalline forms of palonosetron hydrochloride |
| 09/23/2009 | EP2103611A1 Benzoxazole derivatives |
| 09/23/2009 | EP2103610A1 The salts of imidazol-5-carboxylic acid derivatives, preparation methods and use therrof |
| 09/23/2009 | EP2103608A1 Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion |
| 09/23/2009 | EP2103607A1 1-phenyl 1-thio-d-glucitol derivative |
| 09/23/2009 | EP2103603A1 Method for producing pyrrolidine compound |
| 09/23/2009 | EP2103602A1 Novel 1,2,4-triazole derivatives and process of manufacturing thereof |
| 09/23/2009 | EP2103598A1 Fluorinated cycloalkyl-derived benzoylguanidine, method for producing same, use of same as medicine and medicine containing same |
| 09/23/2009 | EP2103307A2 Methylphenidate Modified Release Formulations |
| 09/23/2009 | EP2103306A2 Use of a 5'-nucleotide for preventing/improving functional digestive disorder |
| 09/23/2009 | EP2103305A1 Therapeutic agent for diabetic neuropathy |
| 09/23/2009 | EP2103304A1 Composition for improving brain function |
| 09/23/2009 | EP2103303A2 Controlled release formulation |
| 09/23/2009 | EP2103302A1 Divisible dosage form allowing modified release of the active principle |
| 09/23/2009 | EP2103213A1 Antibacterial agent and bactericidal agent |
| 09/23/2009 | EP2102392A1 Polymorphisms predictive of anthracycline-induced cardiotoxicity |
| 09/23/2009 | EP2102342A2 miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| 09/23/2009 | EP2102245A1 Polyvalent bioconjugates |
| 09/23/2009 | EP2102235A1 Treatment of cachexia |
| 09/23/2009 | EP2102234A2 Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain |
| 09/23/2009 | EP2102226A1 Macrolide compounds endowed with antiinflammatory activity |
| 09/23/2009 | EP2102224A1 CRYSTALLINE FORM OF 1- (ß-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5- (4 -FLUOROPHENYL) -2-THIENYLMETHYL]BENZENE HEMIHYDRATE |
| 09/23/2009 | EP2102222A2 Use of modified oligo-b-(1,3)-glucanes for treating diseases of the immune system, oligo-b- (1,3v-glucane-(1,3)- mannose, oligo-b-(1,3)-glucane-(1,3)- mannitol and derivatives thereof, methods for preparing the same and drugs containing them |
| 09/23/2009 | EP2102219A1 Ibandronate sodium propylene glycol solvate and processes for the preparation thereof |
| 09/23/2009 | EP2102217A2 4- (2-oxo-oxazolidin-3yl)-phenoxymethyle derivativeas as antibacterials |
| 09/23/2009 | EP2102215A1 4,5,6,7-tetrahydro-thieno [2,3-c]pyridines as h3 modulators |
| 09/23/2009 | EP2102214A1 4, 5, 6, 7-tetrahydro-thieno [3, 2-c] pyridine derivatives as h3 modulators |
| 09/23/2009 | EP2102213A1 Improved method for making analgesics |
| 09/23/2009 | EP2102212A1 Imidazolopyrimidines and imidazolotriazine derivatives as inhibitors of poly(adp-ribose) polymerase (parp) |
| 09/23/2009 | EP2102211A2 Heterobicyclic metalloprotease inhibitors |
| 09/23/2009 | EP2102209A2 Novel triazabenzo[a]naphtho[2,l,8-cde]azulene derivatives, method for preparing the same and pharmaceutical compositions containing the same |
| 09/23/2009 | EP2102208A1 Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases |
| 09/23/2009 | EP2102206A1 Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one |
| 09/23/2009 | EP2102204A1 New aminopyrrolo[1,2- a]indole et aminopyridazino[1,6-a]indole derivatives, method for preparing the same and pharmaceutical compositions containing the same |
| 09/23/2009 | EP2102202A2 Conglomerates of tenatoprazole potassium salts |
| 09/23/2009 | EP2102199A1 Antibacterial polycyclic urea compounds |
| 09/23/2009 | EP2102198A1 Sulfonyl-phenyl-2h-[1,2,4]oxodiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
| 09/23/2009 | EP2102197A1 5-([1,3,4]oxadiazol-2-yl)-1h-indazol and 5-([1,3,4]thiadiazol-2-yl)-1h-indazol derivatives as sgk inhibitors for the treatment of diabetes |
| 09/23/2009 | EP2102195A1 Crystal modifications -3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl]-pyrrole-2, 5-d ione |
| 09/23/2009 | EP2102193A1 Piperidine derivative used for treating chemokine receptor 5 mediated diseases |
| 09/23/2009 | EP2102192A1 Solid state forms of racemic ilaprazole |
| 09/23/2009 | EP2102191A1 Crystalline forms of solvated ilaprazole |
| 09/23/2009 | EP2102190A1 Compounds and compositions as kinase inhibitors |
| 09/23/2009 | EP2102189A2 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| 09/23/2009 | EP2102188A2 Compounds |
| 09/23/2009 | EP2102187A1 Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
| 09/23/2009 | EP2102186A1 Indoles |
| 09/23/2009 | EP2102185A1 Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |